We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

3lok

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (16:24, 1 November 2023) (edit) (undo)
 
(7 intermediate revisions not shown.)
Line 1: Line 1:
-
{{Seed}}
 
-
[[Image:3lok.jpg|left|200px]]
 
-
<!--
+
==Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393==
-
The line below this paragraph, containing "STRUCTURE_3lok", creates the "Structure Box" on the page.
+
<StructureSection load='3lok' size='340' side='right'caption='[[3lok]], [[Resolution|resolution]] 2.48&Aring;' scene=''>
-
You may change the PDB parameter (which sets the PDB file loaded into the applet)
+
== Structural highlights ==
-
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+
<table><tr><td colspan='2'>[[3lok]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3LOK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3LOK FirstGlance]. <br>
-
or leave the SCENE parameter empty for the default display.
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.48&#8491;</td></tr>
-
-->
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DJK:N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE'>DJK</scene></td></tr>
-
{{STRUCTURE_3lok| PDB=3lok | SCENE= }}
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3lok FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3lok OCA], [https://pdbe.org/3lok PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3lok RCSB], [https://www.ebi.ac.uk/pdbsum/3lok PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3lok ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/SRC_CHICK SRC_CHICK] Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates involved in this process. When cells adhere via focal adhesions to the extra-cellular matrix, signals are transmitted by integrins into the cell and result in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). Also active at the sites of cell-cell contact adherens junctions and at gap junctions. Implicated in the regulation of pre-mRNA-processing. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus.<ref>PMID:1717492</ref> <ref>PMID:8550628</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Targeting protein kinases in cancer therapy with irreversible small-molecule inhibitors is moving to the forefront of kinase-inhibitor research and is thought to be an effective means of overcoming mutation-associated drug resistance in epidermal growth factor receptor kinase (EGFR). We generated a detection technique that allows direct measurements of covalent bond formation without relying on kinase activity, thereby allowing the straightforward investigation of the influence of steric clashes on covalent inhibitors in different resistant kinase mutants. The obtained results are discussed together with structural biology and biochemical studies of catalytic activity in both wild-type and gatekeeper mutated kinase variants to draw conclusions about the impact of steric hindrance and increased catalytic activity in drug-resistant kinase variants.
-
===Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393===
+
Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.,Kluter S, Simard JR, Rode HB, Grutter C, Pawar V, Raaijmakers HC, Barf TA, Rabiller M, van Otterlo WA, Rauh D Chembiochem. 2010 Dec 10;11(18):2557-66. PMID:21080395<ref>PMID:21080395</ref>
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 3lok" style="background-color:#fffaf0;"></div>
-
<!--
+
==See Also==
-
The line below this paragraph, {{ABSTRACT_PUBMED_21080395}}, adds the Publication Abstract to the page
+
*[[Tyrosine kinase 3D structures|Tyrosine kinase 3D structures]]
-
(as it appears on PubMed at http://www.pubmed.gov), where 21080395 is the PubMed ID number.
+
== References ==
-
-->
+
<references/>
-
{{ABSTRACT_PUBMED_21080395}}
+
__TOC__
-
 
+
</StructureSection>
-
==About this Structure==
+
-
3LOK is a 2 chains structure with sequences from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3LOK OCA].
+
-
 
+
-
==Reference==
+
-
<ref group="xtra">PMID:21080395</ref><references group="xtra"/>
+
[[Category: Gallus gallus]]
[[Category: Gallus gallus]]
-
[[Category: Non-specific protein-tyrosine kinase]]
+
[[Category: Large Structures]]
-
[[Category: Gruetter, C.]]
+
[[Category: Gruetter C]]
-
[[Category: Rauh, D.]]
+
[[Category: Rauh D]]
-
[[Category: Rode, H B.]]
+
[[Category: Rode HB]]
-
[[Category: Atp-binding]]
+
-
[[Category: Covalent inhibitor]]
+
-
[[Category: Drug resistance]]
+
-
[[Category: Irreversible inhibitor]]
+
-
[[Category: Kinase]]
+
-
[[Category: Lipoprotein]]
+
-
[[Category: Myristate]]
+
-
[[Category: Nucleotide-binding]]
+
-
[[Category: Pd168393]]
+
-
[[Category: Phosphoprotein]]
+
-
[[Category: Proto-oncogene]]
+
-
[[Category: Sh2 domain]]
+
-
[[Category: Sh3 domain]]
+
-
[[Category: Src kinase domain]]
+
-
[[Category: Transferase-transferase inhibitor complex]]
+
-
[[Category: Tyrosine-protein kinase]]
+
-
 
+
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Dec 22 09:53:27 2010''
+

Current revision

Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393

PDB ID 3lok

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/3lok"
Personal tools